entertainment -WSS

entertainment

author：fashion 2025-09-30 08:50:18 - browse：5739

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Many breast cancer patients receive more radiation than needed

leisure time

WSS

Russia promises retaliation after Ukrainian drones hit a Russian tanker in 2nd sea attack in a day

Malaysia cuts short music fest after British band slams anti

Doctors have an ethical obligation to be advocates

Where does female orgasm come from? Scientists think they know

How CRISPR works, explained in two minutes

What Henrietta Lacks's story taught me about my role as a doctor

focus

entertainment

explore

ChatGPT in medicine: STAT answers readers' burning questions

Sage considers ways to reduce costs following FDA rejection

Novavax promises a turnaround & Lilly roils the obesity market

Kansas bar where gunfire wounded 9 last month closes permanently

What does generative AI mean for health care? We asked experts

How a key Senate committee is planning to regulate PBMs

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Doctors push to include dialysis machines in emergency stockpile

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Malaysia cuts short music fest after British band slams anti

hotspot

Flash flood warnings continue for parts of Missouri, Illinois

Severe heat forecast: Where scorching temperatures will persist over the next week

New requirements coming in 2024 for Americans traveling to Europe

FAMU bans football players from facility after release of rap video shot in team's locker room

Hundreds of thousands march in Israel. Former security chiefs beg Netanyahu to halt legal overhaul

Slovenia has suffered its worst

focus

hotspot

leisure time

focus